phytoestrogens and Overweight

This paper reported the effects of commonly used whole soy foods (soy flour) and purified daidzein (one of the major isoflavones and the precursor of equol) on changes in anthropometric measurements and body composition in a 6-month double-blind, randomized, placebo-controlled trial among prehypertensive postmenopausal women who are also equol producers.. 270 eligible women were randomized to either one of the three treatments: 40 g soy flour (whole soy group), 40 g low-fat milk powder + 63 mg daidzein (daidzein group), or 40 g low-fat milk powder (placebo group) daily each for 6 months. Anthropometric indicators and body composition were measured before and after intervention.. 253 subjects completed the study with good compliance. Urinary isoflavones levels suggested good compliance of subjects with supplementation. Whole soy and purified daidzein had no significant effect on body weight, body mass index (BMI), waist and hip circumferences, waist to hip ratio (WHR), body fat percentage, fat mass, and free fat mass.. Six-month consumption of whole soy and purified daidzein at provided dosage had no improvement on body weight and composition compared with isocaloric milk placebo among prehypertensive equol-producing postmenopausal women. This trial is registered with ClinicalTrials.gov NCT01270737.

Topics: Adiposity; Aged; Analysis of Variance; Body Composition; Body Mass Index; Body Weight; Double-Blind Method; Equol; Female; Hong Kong; Humans; Isoflavones; Middle Aged; Overweight; Phytoestrogens; Postmenopause; Predictive Value of Tests; Prehypertension; Soy Foods; Time Factors; Treatment Outcome; Waist Circumference; Waist-Hip Ratio

In postmenopause, ovarian decline along with sedentary lifestyle could contribute to the loss of lean body mass (LBM) and muscle strength. This study aimed to verify whether exercise and isoflavones could have additive effects on muscle quality, muscle mass index, relative strength and physical capacity in overweight sedentary postmenopausal women.. We recruited 70 overweight-to-obese (body mass index 32.2±4.8 kg/m(2)) postmenopausal women (59±5 years old) to participate in a 6-month clinical study combining isoflavones (70 mg/day) and exercise (resistance and aerobic training) treatments. Subjects were divided into four groups: (1) placebo (n =15), (2) isoflavones (n =15), (3) exercise and placebo (n =20), and (4) exercise and isoflavone (n =20). Principal outcome variables included maximal muscle strength (1RM) at the leg press and the bench press, muscle mass index, muscle quality in the legs and relative strength.. After 6 months of training, exercise produced 49% and 23% increases, respectively, in leg press and bench press 1RM (p ≤0.01). Leg relative strength and muscle quality increased by more than 50% (both p <0.01), while muscle mass index increased by 7% (p <0.05) in both exercise groups only.. Exercise training can improve muscle tissue strength, function and quality in sedentary postmenopausal women. Isoflavones, irrespective of exercise, did not produce changes in these variables. From a clinical perspective, these results suggest that overweight women could reduce the risks of mobility impairments, even in the absence of weight loss, by following a sound exercise intervention that includes both resistance and aerobic training at a high intensity.

Topics: Bicycling; Exercise Tolerance; Female; Glycine max; Humans; Isoflavones; Middle Aged; Muscle Strength; Muscle, Skeletal; Overweight; Physical Fitness; Phytoestrogens; Postmenopause; Resistance Training; Sedentary Behavior

Epidemiologic studies indicate that soy intake has an important role in the prevention of age-related health problems. Daidzein, the principal isoflavone contained in soy, is converted to S-equol by the intestinal bacteria. Not all individuals, however, can produce S-equol, which is considered the most biologically active metabolite. We studied the effects of a natural S-equol supplement on metabolic parameters associated with overweight or obesity and metabolic syndrome.. The study was a randomized, double-blinded, placebo-controlled, crossover design with no washout period. All subjects were considered overweight or obese if they had a body mass index ≥ 25 kg/m(2) . Placebo or natural S-equol tablets containing 10 mg S-equol were orally ingested each day for 12 weeks. A total of 54 Japanese overweight or obese outpatients were enrolled. The equol phenotype was determined, and various metabolic parameters, including cardio-ankle vascular index (CAVI), were measured.. Equol non-producers comprised 67.9% of the overweight or obese subjects. The ratio of equol non-producers in this overweight or obese subject group was higher than the previously reported ratio of equol non-producers (approximately 50%) in the general population. Compared with the placebo group, intervention with natural S-equol led to a significant decrease in HbA1c, serum low-density lipoprotein cholesterol (LDL-C) levels and CAVI score. Furthermore, the effect was more prominent in the subgroup of female equol non-producers.. The ratio of equol non-producers in overweight or obese populations might be higher than generally reported. Natural S-equol might have a role in glycaemic control and in the prevention of cardiovascular disease by its effects to lower LDL-C levels and CAVI scores in overweight or obese individuals.

Topics: Asian People; Cholesterol, LDL; Dietary Supplements; Equol; Female; Glycated Hemoglobin; Humans; Male; Metabolic Syndrome; Obesity; Overweight; Phytoestrogens

Postmenopausal women seem to favor alternative therapies such as exercise and phytoestrogens as a substitute for potentially harmful hormone replacement therapy. Based on previous research, we hypothesized that phytoestrogens combined with exercise could have a synergic effect on women's health.. To verify whether phytoestrogens enhance the response to mixed training regarding menopausal symptoms and quality of life in postmenopausal women.. From a pool of women participating in a 6-month randomized, controlled exercise study, 21 received a placebo (mean age 58.3 ± 5.4 years, body mass index 29.8 ± 5.1 kg/m(2)) and 19 received phytoestrogen supplements (mean age 60.1 ± 3.4 years; body mass index 30.3 ± 4.6 kg/m(2)). Body weight, fat mass and lean body mass (dual-energy X-ray absorptiometry) were assessed. Quality of life was estimated by the Short Form-36 (SF-36) and Perceived Stress Scale-10 (PSS-10) questionnaires, and menopausal symptoms by the Kupperman index. All measurements were performed before and after the intervention.. Although the Kupperman index and PSS-10 remained unchanged in both groups, the SF-36 Physical Component Summary and almost all the SF-36 subscales (except for role-emotional and mental health) increased only in the exercise group taking phytoestrogens (0.001 < p < 0.04).. While phytoestrogens combined with mixed exercise were not sufficient to improve menopausal symptoms, it seemed to be a better strategy than exercise alone to improve the general quality of life in postmenopausal women.

Topics: Body Mass Index; Dietary Supplements; Exercise; Female; Hot Flashes; Humans; Middle Aged; Obesity; Overweight; Phytoestrogens; Placebos; Postmenopause; Quality of Life

There has been substantial interest in phytoestrogens, because of their potential effect in reducing cancer and heart disease risk. Measuring concentrations of phytoestrogens in urine is an alternative method for conducting epidemiological studies. Our objective was to evaluate the urinary excretion of phytoestrogens as biomarkers for dietary phytoestrogen intake in Mexican women. Participants were 100 healthy women from 25 to 80 years of age. A food frequency questionnaire (FFQ) and a 24 h recall were used to estimate habitual and recent intakes of isoflavones, lignans, flavonols, coumestrol, resveratrol, naringenin, and luteolin. Urinary concentrations were measured by liquid chromatography (HPLC) coupled to mass spectrometry (MS) using the electrospray ionization interface (ESI) and diode array detector (DAD) (HPLC-DAD-ESI-MS). Spearman correlation coefficients were used to evaluate associations between dietary intake and urine concentrations. The habitual consumption (FFQ) of total phytoestrogens was 37.56 mg/day. In urine, the higher compounds were naringenin (60.1 µg/L) and enterolactone (41.7 µg/L). Recent intakes (24 h recall) of isoflavones (

Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Cross-Sectional Studies; Diet, Healthy; Female; Heart Diseases; Humans; Mexico; Middle Aged; Neoplasms; Nutrition Surveys; Obesity; Overweight; Patient Compliance; Phytoestrogens; Prevalence; Risk

Tissue-selective estrogen complex (TSEC), which combines a selective estrogen receptor modulator (SERM) with one or more estrogens, is a novel approach to menopausal therapy. It has been demonstrated that the phytoestrogen genistein (GEN) exhibits mixed estrogen receptor agonist and antagonist activity, suggesting that GEN may have potential for use as a natural SERM. We evaluated, for the first time, the effects of GEN, conjugated estrogens (CE), and their pairing effects as a TSEC treatment on estrogen-induced endometrial hyperplasia and metabolic dysfunction in ovariectomized (OVX) mice fed a high-fat diet. CE replacement prevented fat accumulation in the adipose tissue and liver, improved glucose homeostasis, and induced endometrial hyperplasia in OVX mice. GEN at 100 mg/kg showed CE mimetic effects in preventing ovariectomy-induced metabolic dysfunctions without endometrial stimulation. Combination treatments with CE and GEN prevented metabolic dysfunctions more strongly than CE alone, but at both low and high doses, GEN did not reverse CE-induced endometrial hyperplasia. In addition, we found that in a TSEC regimen, a typical SERM raloxifene maintains the metabolic benefits of CE while simultaneously protecting the endometrium in OVX mice. These findings indicate that GEN acts as an estrogen agonist in metabolic regulation, but has no SERM function in the uteri of OVX mice.

Topics: Adiposity; Animals; Diet, High-Fat; Dietary Supplements; Endometrial Hyperplasia; Endometrium; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Genistein; Glucose Intolerance; Liver; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Ovariectomy; Overweight; Phytoestrogens; Raloxifene Hydrochloride; Random Allocation; Selective Estrogen Receptor Modulators